Prelude Therapeutics
Focus: Prelude Therapeutics is an early-stage oncology-focused biotech founded in 2016, developing targeted cancer treatments across multiple tumor types. The company operates as a pre-revenue biotech with a portfolio of Phase 1 programs.
Profile data last refreshed 13h ago · AI intelligence enriched 2mo ago
Open Jobs
1-1 this month
Stable — net -1 jobs in 30d
1 added, 2 removed. Backfill posture.
Should You Work at Prelude Therapeutics?
AI assessmentPrelude is a nascent oncology play suitable for early-career scientists and clinicians seeking equity upside and mentorship in drug discovery, but not for those prioritizing near-term clinical wins or financial transparency.
Why Work Here
- Exposure to a diversified oncology pipeline with 10 active clinical trials across hematologic malignancies, solid tumors, and rare blood disorders
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
13 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
aScope™ Duodeno endoscope and aBox™ Duodeno
Endoscopic Retrograde Cholangiopancreatography (ERCP)PRT3789
Advanced Solid TumorClinical Trials (1)
Help build intelligence for Prelude Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.